DVA vs EHC
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DVA · DaVita$191.35 ▼ 1.78%
EHC · Encompass Health$137.54 ▼ 2.64%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DVA +59.2%
- EHC +20.1%
Head to head
| Metric | DVA | EHC |
|---|---|---|
| Price | $191.35 | $137.54 |
| Change today | ▼ 1.78% | ▼ 2.64% |
| Market cap | $12.04B | $13.50B |
| Return, 3 months | +4.2% | +9.3% |
| Return, year to date | +68.4% | +30.3% |
| Return, 1 year | +54.7% | +20.0% |
| P/E (TTM) | 14.2 | 21.5 |
| P/B | -20.4 | 5.0 |
| P/E percentile vs own 5y | 61st | 43rd |
| Dividend yield | – | 0.57% |
| Revenue growth (YoY, latest qtr) | +4.6% | +9.6% |
| Net profit growth (YoY) | +12.1% | +12.2% |
| Gross margin | 32.3% | 95.8% |
| Operating margin | 15.2% | 18.0% |
| Net margin | 6.5% | 10.0% |
| Return on equity | – | 25.4% |
| Analyst target vs. price | +15.4% | +10.7% |
| Analyst buy share | 40% | 100% |
| RSI (14) | 56 | 64 |
| 30-day volatility | 39.8% | 38.6% |
| Max drawdown, 1 year | -27.9% | -26.1% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- EHC is the largest of the group by market value.
- DVA has returned the most over the past year.
- DVA carries the lowest trailing P/E.
- EHC is growing revenue fastest.
- EHC keeps the most profit per dollar of sales.
- EHC has been the calmest stock over the last 30 days.